Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Net Margin (2021 - 2025)

Historic Net Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Q3 2025 value amounting to 105.81%.

  • Rhythm Pharmaceuticals' Net Margin rose 294300.0% to 105.81% in Q3 2025 from the same period last year, while for Sep 2025 it was 113.41%, marking a year-over-year increase of 1190100.0%. This contributed to the annual value of 203.32% for FY2024, which is 352000.0% up from last year.
  • Rhythm Pharmaceuticals' Net Margin amounted to 105.81% in Q3 2025, which was up 294300.0% from 98.93% recorded in Q2 2025.
  • In the past 5 years, Rhythm Pharmaceuticals' Net Margin ranged from a high of 125000.0% in Q1 2021 and a low of 12915.69% during Q2 2021
  • Over the past 5 years, Rhythm Pharmaceuticals' median Net Margin value was 242.98% (recorded in 2023), while the average stood at 5163.35%.
  • The largest annual percentage gain for Rhythm Pharmaceuticals' Net Margin in the last 5 years was 124207900bps (2022), contrasted with its biggest fall of -1285067400bps (2022).
  • Over the past 5 years, Rhythm Pharmaceuticals' Net Margin (Quarter) stood at 2798.84% in 2021, then soared by 83bps to 483.42% in 2022, then skyrocketed by 64bps to 171.8% in 2023, then soared by 38bps to 106.7% in 2024, then rose by 1bps to 105.81% in 2025.
  • Its last three reported values are 105.81% in Q3 2025, 98.93% for Q2 2025, and 155.39% during Q1 2025.